ASCT is currently the "gold standard" first line treatment for multiple myeloma patients younger than 65 years old, limited data on efficacy and safety in older patients are available METHODS: We retrospectively analyzed a cohort of 83 newly diagnosed multiple myeloma patients aged 65 or older. All patients were evaluated for fitness at diagnosis and after bortezomib-based induction treatment.
Autologous stem cell transplantation is safe in selected elderly multiple myeloma patients / Antonioli, Elisabetta; Nozzoli, Chiara; Buda, Gabriele; Staderini, Michela; Boncompagni, Riccardo; Martini, Francesca; Petrini, Mario; Bosi, Alberto; Saccardi, Riccardo. - In: EUROPEAN JOURNAL OF HAEMATOLOGY. - ISSN 0902-4441. - STAMPA. - (2019), pp. 200-208. [10.1111/ejh.13357]
Autologous stem cell transplantation is safe in selected elderly multiple myeloma patients
Antonioli, Elisabetta;Nozzoli, Chiara;Staderini, Michela;Boncompagni, Riccardo;Martini, Francesca;Bosi, Alberto;Saccardi, Riccardo
2019
Abstract
ASCT is currently the "gold standard" first line treatment for multiple myeloma patients younger than 65 years old, limited data on efficacy and safety in older patients are available METHODS: We retrospectively analyzed a cohort of 83 newly diagnosed multiple myeloma patients aged 65 or older. All patients were evaluated for fitness at diagnosis and after bortezomib-based induction treatment.
I documenti in FLORE sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
